Utang jangka cendhak perusahaan: Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics production capacities are fully utilized in the creation of oncology drugs using calibrated equipment. Innovative molecules for immune stimulation will ensure premium pricing following regulatory approval. However, high burn rates and dependence on clinical trials create risks. The company's short-term liabilities on the chart reflect borrowing dynamics, and 0.00 shows the current value of the metric.

This indicator captures the total volume of credit obligations with maturities of up to one year, reflecting the actual liquidity burden absent market volatility. An analysis of short-term balance sheet liabilities allows for an assessment of the cash gap risk for Tempest Therapeutics (TPST), whose financial stability depends critically on the success of costly oncology research and the ability to raise capital for R&D.